For teens with HIV, a shot every two months beats daily pills

The LATA trial followed 476 adolescents aged 12 to 19 at five clinics in Kenya, South Africa, Uganda and Zimbabwe, comparing injections of cabotegravir plus rilpivirine every eight weeks with daily tablets. After 96 weeks, the virus rebounded in only 2 teens (1%) on injections versus 15 (6%) on tablets, and 94% of the injection group said it was much easier than daily pills. Published in The Lancet; chief investigator Prof. Sarah Pett of UCL. About 1.6 million adolescents aged 10 to 19 live with HIV worldwide — 9 in 10 of them in Africa.